Logotype for Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics (LCTX) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Lineage Cell Therapeutics Inc

Corporate presentation summary

16 Nov, 2026

Platform and pipeline

  • AlloSCOPE uses pluripotent stem cell expansion and guided differentiation to produce 200+ cell types, targeting scalable, consistent, off-the-shelf therapies.

  • 5D uses microcarriers as a 2D surface in a 3D bioreactor, aiming for controlled differentiation with less handling and lower aseptic risk.

  • GMP-scale production was demonstrated using two cell lines and cell types; product vial capability is 1M–20M, with automated fill-finish needed for the upper range.

  • Pipeline includes 7 cell types in development, 2 active clinical trials, and ~375 issued and pending patents.

  • Cash, cash equivalents and marketable securities totaled $50.8M as of June 30, 2026.

OpRegen

  • Roche and Genentech lead clinical development and commercialization under a 2021 license; terms include $50M upfront, a $5M milestone received in Dec 2025, up to $615M in additional milestones and double-digit royalties.

  • Phase 1/2a Cohort 4 showed mean visual acuity gains of +6.2 ETDRS letters at 36 months; the extensive-bleb subgroup (n=5) gained +9.0 letters.

  • All 5 patients with extensive bleb coverage showed retinal structural improvement; improvement was observed within 3 months and only within lesions covered by the bleb.

  • The Genentech-sponsored GAlette Phase 2a study evaluates delivery, safety and preliminary activity; enrollment is up to 60 across 17 U.S. and Israel sites.

  • The program has FDA Fast Track and RMAT designations and potential application in other retinal diseases, including Stargardt disease.

OPC1

  • More than 30 patients have been treated; cervical and thoracic studies reported no unexpected serious adverse events related to transplantation, with follow-up of at least 8 and 14 years, respectively.

  • In cervical Cohort 2, 4 of 6 subjects gained at least 2 motor levels on one side at 12 months and 5 of 6 at 24 months; no enrolled patients had worsening neurological function.

  • Among 25 treated subjects, no serious adverse events were related to OPC1 cells; safety data spans 2–5 years.

  • At 24 months, 24 of 25 patients had serial MRI scans showing no lesion cavity, based on 22 available scans.

  • The DOSED study evaluates a new delivery device in 6–10 patients, including 3–5 subacute and 3–5 chronic injuries; preparations are underway for a larger controlled trial.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Lineage Cell Therapeutics